• Home
  • High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

Author List
Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH
Publication
Leukemia & lymphoma
Publication ID (Profile URL)
https://researcherprofiles.org/profile/22499281
Publication Year
2018
PubMed ID
30032678
Publication Title
Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452.